Kyverna Therapeutics has appointed two seasoned biotech executives to its Board of Directors as the company prepares to bring its cell therapy pipeline to market. Sravan K. Emany, currently serving as Chief Financial Officer of Beam Therapeutics, and Andrew Miller, former Chief Medical Officer of Karuna Therapeutics, join the board to guide Kyverna's commercial expansion in the autoimmune disease space.
Emany brings extensive experience in capital markets and rare disease commercialization from his tenure at Beam, a publicly traded cell therapy company. Miller brings significant clinical development and regulatory approval expertise, having held leadership roles at Karuna and earning recognition as a Time Magazine honoree for his work advancing psychiatric treatments.
The appointments mark a strategic shift for Kyverna as it advances toward commercialization milestones. Dan Spiegelman has stepped down from his board position. The company's cell therapy candidates target various autoimmune conditions, a therapeutic area that has seen increasing investor interest and regulatory progress in recent years.